He Reversed Alzheimer’s Biomarkers in 9 Weeks — Here’s How It Could Help Lyme+
This week on Lyme Time: Dr. Richard Horowitz — 42 years, 13,000 patients, a leading voice in tick-borne illness — joins me to break down his new book, Ending Chronic Illness, and the research turning heads.
- His MSIDS model maps 16 inflammatory contributors to chronic illness: infections, toxins, immune dysfunction, mitochondrial damage, hormones, gut health, and more. The core idea: stop naming diseases and treating symptoms — find where the inflammation is coming from.
- Dr. Horowitz was recently published in the Journal of Alzheimer’s Disease Reports: a chronic Lyme patient’s PTau217 (top Alzheimer’s biomarker) dropped 63% in 9 weeks on Dapsone combination therapy — compared to ~23-29% over seven years for leading anti-amyloid drugs. Her cognition improved too, though this is case-study evidence; a randomized trial is next.
- The protocol itself: a nine-week pulsed, oral, generic antibiotic combo (doxycycline/minocycline + rifampin + Dapsone) targeting dormant “biofilm persister” forms of Borrelia, discovered around 2015. Short-term, not long-term — often insurance-covered.
- Horowitz says the same 16 factors show up in long COVID, autism, ADHD, chronic fatigue, and autoimmune disease — pointing to a shared inflammatory root.
- His wife battled illness for 25 years with all 16 MSIDS factors. She’s now 8 years in remission.
📚 Ending Chronic Illness — releases October 13. Preorder at cangetbetter.com.
I hope you check it out!
